STOCK TITAN

Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Azora Therapeutics (AZR) granted one new non-executive employee an option to buy 40,000 common shares as a hiring inducement. The grant took effect on November 16, 2026, under the 2026 Employment Inducement Equity Incentive Plan. The option has a $3.81-per-share exercise price, equal to the stock’s closing price on that date, and a ten-year term.

The option vests over four years: 25% on the first anniversary of the grant date and the rest in equal monthly installments, subject to continued service through each vesting date.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Option for 40,000 common shares could dilute existing shareholders if exercised at $3.81 per share.

Key Figures

Option award: 40,000 shares Exercise price: $3.81 per share Option term: 10 years +1 more
Option award
40,000 shares
Granted to one new non-executive employee
Exercise price
$3.81 per share
Closing price on the effective grant date
Option term
10 years
Option award
Vesting schedule
25% on the first anniversary; remainder in equal monthly installments over four years
Subject to continued service through each applicable vesting date

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (NASDAQ: AZR) (the “Company”), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company’s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The option award has an exercise price of $3.81 per share, the closing price of the Company’s common stock on November 16, 2026, the effective date of grant, and has a ten-year term. The option award will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to the recipient’s continued service through each applicable vesting date. The option award is subject to the terms and conditions of the 2026 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company or its parent or subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

About Azora Therapeutics, Inc.

Azora Therapeutics is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was launched out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns worldwide royalty-free rights to its technology, which is based on the development of oral agonists of the aryl hydrocarbon receptor. Azora’s lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, in development for ulcerative colitis. More information on Azora can be found on the company’s website at www.AzoraTherapeutics.com.

Investor Contact:

Mike Moyer
Managing Director
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.com 

Media Contact:

Ashley Biladeau
Inizio Evoke Comms
Email: Ashley.Biladeau@inizioevoke.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does Azora Therapeutics’ inducement option cover, and what is the exercise price?

The inducement option covers 40,000 common shares at $3.81 per share. The exercise price matched the stock’s closing price on November 16, 2026, the grant’s effective date. The option has a ten-year term.

Who is eligible for awards under Azora Therapeutics’ 2026 Employment Inducement Equity Incentive Plan?

The plan is limited to new hires and individuals returning after a genuine period of non-employment. Awards are used as a material inducement to join Azora; the new-hire category excludes anyone previously employed by Azora, its parent or its subsidiaries.

Keep reading